Zusammenfassung
Eine Barrett-Schleimhaut ist eine histologische Diagnose, da der Nachweis einer Becherzelle histologisch geführt werden muss. Da die Barrett-Schleimhaut per se schon eine Metaplasie darstellt, sind die klassischen Kriterien einer Neoplasie im Gastrointestinaltrakt zuweilen nicht einfach anwendbar bzw. können reaktive Veränderungen im Einzelfall schwer von einer Neoplasie abgrenzbar sein. Im Manuskript sollen die Hintergründe der histologischen Diagnose so aufgezeigt werden, dass die klinisch-diagnostischen Erwartungen an die Pathologie mit den Möglichkeiten der histopathologischen Diagnostik übereinstimmen. Wenn alle Beteiligten diese Umstände kennen, wenn Hintergründe klar sind und sich dann zusätzliche Möglichkeiten der Abschätzung des weiteren therapeutischen Vorgehens ergeben, kann die Interaktion zwischen Klinik und Pathologie weiter intensiviert werden.
Abstract
Barrett’s mucosa is a histological diagnosis, since goblet cells must be present in the histological assessment of biopsies. Barrett’s mucosa is already a metaplasia; therefore, the classic criteria for neoplasia in the gastrointestinal tract may not always be easy to apply and reactive changes can be difficult to distinguish from neoplasia in individual cases. In this article, the background for the histological diagnosis is presented such that the clinical expectations of the pathology report correspond to the histopathological possibilities. This interaction is further intensified when everyone involved is aware of the circumstances and the background is clear, thus, possibly resulting in additional options arising to assess further therapeutic procedures.
Literatur
Faller G (2002) Histopathologische Diagnostik der Barrett-Schleimhaut und ihrer Neoplasien: Ergebnisse einer Konsensus-Konferenz der Arbeitsgemeinschaft Gastroenterologische Pathologie der Deutschen Gesellschaft für Pathologie am 22. September 2001 in Erlangen. Verh Dtsch Ges Pathol 86:126–130
Lomo LC, Blount PL, Sanchez CA, Li X, Galipeau PC, Cowan DS, Ayub K, Rabinovitch PS, Reid BJ, Odze RD (2006) Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett’s esophagus cohort. Am J Surg Pathol 30(4):423–435. https://doi.org/10.1097/00000478-200604000-00001
Schmidt HG, Riddell RH, Walther B, Skinner DB, Riemann JF (1985) Dysplasia in Barrett’s esophagus. J Cancer Res Clin Oncol 110(2):145–152. https://doi.org/10.1007/BF00402729
Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, Goldblum J, Gordon C, Grabsch H, Haigh C, Hongo M, Johnston D, Forbes-Young R, Kay E, Kaye P, Lerut T, Lovat LB, Lundell L, Mairs P, Shimoda T, Spechler S, Sontag S, Malfertheiner P, Murray I, Nanji M, Poller D, Ragunath K, Regula J, Cestari R, Shepherd N, Singh R, Stein HJ, Talley NJ, Galmiche JP, Tham TC, Watson P, Yerian L, Rugge M, Rice TW, Hart J, Gittens S, Hewin D, Hochberger J, Kahrilas P, Preston S, Sampliner R, Sharma P, Stuart R, Wang K, Waxman I, Abley C, Loft D, Penman I, Shaheen NJ, Chak A, Davies G, Dunn L, Falck-Ytter Y, Decaestecker J, Bhandari P, Ell C, Griffin SM, Attwood S, Barr H, Allen J, Ferguson MK, Moayyedi P, Jankowski JA (2012) Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 143(2):336–346. https://doi.org/10.1053/j.gastro.2012.04.032
Vieth M, Montgomery EA, Riddell RH (2016) Observations of different patterns of dysplasia in barretts esophagus—a first step to harmonize grading. Cesk Patol 52(3):154–163
Madisch A, Koop H, Miehlke S, Leers J, Lorenz P, Jansen PL, Pech O, Schilling D, Labenz J (2023) Update S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis
Filipe MI, Potet F, Bogomoletz WV, Dawson PA, Fabiani B, Chauveinc P, Fenzy A, Gazzard B, Goldfain D, Zeegen R (1985) Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut 26(12):1319–1326. https://doi.org/10.1136/gut.26.12.1319
Bogdanova I, Polaka I, Aleksandraviča I, Dzērve Z, Anarkulova L, Novika V, Tolmanis I, Leja M (2023) Role of pre-existing incomplete intestinal metaplasia in gastric adenocarcinoma: a retrospective case series analysis. World J Clin Cases 11(12):2708–2715. https://doi.org/10.12998/wjcc.v11.i12.2708
Petersson F, Borch K, Franzén LE (2002) Prevalence of subtypes of intestinal metaplasia in the general population and in patients with autoimmune chronic atrophic gastritis. Scand J Gastroenterol 37(3):262–266. https://doi.org/10.1080/003655202317284156
Meining A, Morgner A, Miehlke S, Bayerdörffer E, Stolte M (2001) Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? Best Pract Res Clin Gastroenterol 15(6):983–998. https://doi.org/10.1053/bega.2001.0253
Pohl H, Pech O, Arash H, Stolte M, Manner H, May A, Kraywinkel K, Sonnenberg A, Ell C (2016) Length of Barrett’s oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut 65(2):196–201. https://doi.org/10.1136/gutjnl-2015-309220
Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, Jankowski JA, Junghard O, Lundell L, Tytgat GN, Vieth M (2006) The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 131(5):1392–1399. https://doi.org/10.1053/j.gastro.2006.08.032
Levink IJM, Tearney GJ, Erler NS, Wolfsen HC, Siersema PD, Wallace MB (2021) Barrett’s epithelial thickness, assessed by volumetric laser endomicroscopy, is associated with response to radiofrequency ablation. Clin Gastroenterol Hepatol 19(6):1160–1169.e2. https://doi.org/10.1016/j.cgh.2020.05.023
Vieth M, Stolte M (2005) Pathology of early upper GI cancers. Best Pract Res Clin Gastroenterol 19(6):857–869. https://doi.org/10.1016/j.bpg.2005.02.008
Westerterp M, Koppert LB, Buskens CJ, Tilanus HW, ten Kate FJ, Bergman JJ, Siersema PD, van Dekken H, van Lanschot JJ (2005) Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 446(5):497–504. https://doi.org/10.1007/s00428-005-1243-1
Waters KM, Salimian KJ, Assarzadegan N, Hutchings D, Makhoul EP, Windon AL, Wong MT, Voltaggio L, Montgomery EA (2021) Cell polarity (the ‘four lines’) distinguishes gastric dysplasia from epithelial changes in reactive gastropathy. Histopathology 78(3):453–458. https://doi.org/10.1111/his.14242
Wani S, Rubenstein JH, Vieth M, Bergman J (2016) Diagnosis and management of low-grade dysplasia in Barrett’s esophagus: expert review from the clinical practice updates committee of the American gastroenterological association. Gastroenterology 151(5):822–835. https://doi.org/10.1053/j.gastro.2016.09.040
Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O’Connell S, Seidel UJ, Sonnenberg A (2001) Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology 120(7):1607–1619. https://doi.org/10.1053/gast.2001.25065
Krugmann J, Vieth M, Neumann H (2014) Barrett-Neoplasie: Wo liegt eigentlich das Problem? Zentralbl Chir 139(4):386–392. https://doi.org/10.1055/s-0033-1360296
Duits LC, Phoa KN, Curvers WL, ten Kate FJ, Meijer GA, Seldenrijk CA, Offerhaus GJ, Visser M, Meijer SL, Krishnadath KK, Tijssen JG, Mallant-Hent RC, Bergman JJ (2015) Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut 64(5):700–706. https://doi.org/10.1136/gutjnl-2014-307278
Borchard F (2000) Formen und Nomenklatur der gastrointestinalen Epithelexpansion: Was ist Invasion? Verh Dtsch Ges Pathol 84:50–61
Mino-Kenudson M, Hull MJ, Brown I, Muzikansky A, Srivastava A, Glickman J, Park DY, Zuckerberg L, Misdraji J, Odze RD, Lauwers GY (2007) EMR for Barrett’s esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc 66(4):660–666. https://doi.org/10.1016/j.gie.2007.02.063 (quiz 767, 769)
Vieth M, Stolte M (2002) Barrett’s esophagus and neoplasia: data from the Bayreuth Barrett’s archive. Gastroenterology 122(2):590–591. https://doi.org/10.1053/gast.2002.31600
Januszewicz W, Pilonis ND, Sawas T, Phillips R, O’Donovan M, Miremadi A, Malhotra S, Tripathi M, Blasko A, Katzka DA, Fitzgerald RC, di Pietro M (2022) The utility of P53 immunohistochemistry in the diagnosis of Barrett’s oesophagus with indefinite for dysplasia. Histopathology 80(7):1081–1090. https://doi.org/10.1111/his.14642
Fléjou JF (2005) Barrett’s oesophagus: from metaplasia to dysplasia and cancer. Gut 54(1):i6–12. https://doi.org/10.1136/gut.2004.041525
Villanacci V, Salemme M, Stroppa I, Balassone V, Bassotti G (2017) The importance of a second opinion in the diagnosis of Barrett’s esophagus: a ”real life“ study. Rev Esp Enferm Dig 109(3):185–189. https://doi.org/10.17235/reed.2016.4505/2016
Montgomery E (2009) Refining diagnostic criteria for high-grade dysplasia in Barrett esophagus. Am J Clin Pathol 132(1):7–9. https://doi.org/10.1309/AJCPPCJC71IFRVVG
Rucker-Schmidt RL, Sanchez CA, Blount PL, Ayub K, Li X, Rabinovitch PS, Reid BJ, Odze RD (2009) Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol 33(6):886–893. https://doi.org/10.1097/PAS.0b013e318198a1d4
Sakurai U, Lauwers GY, Vieth M, Sawabe M, Arai T, Yoshida T, Aida J, Takubo K (2014) Gastric high-grade dysplasia can be associated with submucosal invasion: evaluation of its prevalence in a series of 121 endoscopically resected specimens. Am J Surg Pathol 38(11):1545–1550. https://doi.org/10.1097/PAS.0000000000000274
Manner H, May A, Pech O, Gossner L, Rabenstein T, Günter E, Vieth M, Stolte M, Ell C (2008) Early Barrett’s carcinoma with “low-risk” submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 103(10):2589–2597. https://doi.org/10.1111/j.1572-0241.2008.02083.x
Wittekind C (Hrsg) (2017) TNM Klassifikation maligner Tumoren, 8. Aufl. Wiley-VCH, Weinheim, S 123 ISBN 978-3-527-34280‑8.
Tsukashita S, Kushima R, Bamba M, Sugihara H, Hattori T (2001) MUC gene expression and histogenesis of adenocarcinoma of the stomach. Int J Cancer 94(2):166–170. https://doi.org/10.1002/ijc.1460
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Vieth gibt an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
Irene Esposito, Düsseldorf
Andrea Tannapfel, Bochum
Eva Wardelmann, Münster
Hinweis des Verlags
Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Vieth, M., Sterlacci, W. Barrett-Schleimhaut und Neoplasie. Gastroenterologie (2024). https://doi.org/10.1007/s11377-024-00782-y
Accepted:
Published:
DOI: https://doi.org/10.1007/s11377-024-00782-y